Organic Active Ingredients TRIZ Cases

Genome editing system generates blunt-ended DNA breaks to excise intron segments and restore functional donor splice sites.

Porous silicon particles enable sustained intraocular drug delivery through diffusion and degradation, eliminating frequent invasive injections.

Aryl analogs modulate the NRF2 pathway to address inadequate oxidative stress management, slowing disease progression in COPD and asthma.

Incorporating bicyclic amino acid residues into inhibitor structures enhances oral bioavailability while maintaining specific Cathepsin C inhibition.

BET, IKK, JAK, PDK1, and Syk inhibitors maintain T cells in less differentiated states during ex vivo expansion to improve therapeutic efficacy.

ASO-mediated depletion of lnc-HLX-2-7 reduces proliferation and induces apoptosis, resolving side effects from conventional therapies.

Aceclidine formulation resolves presbyopia treatment contradictions by improving depth of focus while minimizing distance blur and retinal detachment risks.

A hypocaloric tube feed formulation combines multiple protein sources with processed whole foods to deliver complete nutrition.

Inhibiting HIF prolyl hydroxylases increases endogenous erythropoietin production, treating anemia without exogenous therapy risks.

Developing cyclic compounds that block TLR4 signaling resolves the lack of effective inhibitors for chemotherapy-induced peripheral neuropathy.

Esterifying tocotrienols with nicotinic acid improves stability and bioavailability in cosmetic formulations.

Ginseng extract reduces metal ions to nanoparticles and stabilizes the surface, eliminating costly chemical agents.

Novel benzoic acid derivatives modify terminal groups to enhance metabolic stability and reduce toxicity in pharmaceutical applications.

Hydrophobic polymer coating prevents alcohol-induced dose dumping in sustained-release oral pharmaceutical forms.

Indoline compounds selectively inhibit HDAC6 while activating Nrf2 and HIF to treat neurological disorders with reduced side effects.

Optimizing phospholipid and surfactant concentrations creates homogeneous, stable foams that resolve development time bottlenecks in topical drug formulation.

Autophagy and DCAR-1 inhibitors overcome drug resistance by blocking parasite recovery.

BO-110 polycationic complexes protect unstable dsRNA from degradation while selectively killing melanoma cells via dual autophagy and apoptosis induction.

Characterizing novel Riociguat polymorphs resolves stability issues, enabling reliable drug formulation.

Crystallization inhibitors prevent active agent crystallization in medical adhesives, ensuring predictable drug release while preserving adhesive tack.

Selective PAR-4 antagonists reduce bleeding risks while maintaining antithrombotic efficacy in thromboembolic disorders.

Modified compounds overcome poor brain penetration of current therapies, enhancing CNS concentration and therapeutic efficacy.

CAP7.1 prodrugs bypass ABC transporter resistance to kill cancer stem cells and prevent tumor relapse.

TG02 polymorphs inhibit CDKs, JAK2, and FLT3 simultaneously, overcoming limited efficacy of single-target kinase inhibitors.

Antibody-drug conjugates deliver exatecan payloads via cathepsin B cleavable linkers to cancer cells.

Tricyclic fused thiophene derivatives modulate Janus kinase activity through specific structural substitution patterns.

Adjusting formulation parameters to basic pH and low water content resolves the solubility stability contradiction while reducing urothelial toxicity.

Replacing immunogenic antibodies with small molecule targeting groups eliminates tolerance issues while sustaining long-term tumor growth inhibition.

A biotin moiety conjugates to physiologically active substances to enhance oral absorption via sodium-dependent multivitamin transporters.

Antisense oligonucleotides inhibit miR-27a and miR-182 clusters, reducing fibrosis caused by bile acid toxicity in cholestasis.

Montbretin A inhibits human pancreatic alpha-amylase through specific binding, reducing postprandial glucose spikes without gastrointestinal side effects.

Administering hepatocyte growth factor nucleic acid sequences prior to surgery resolves revascularization inefficiency and improves skin flap survival rates.

Biaryl cyclohexene compounds inhibit CETP to raise HDL-C and lower LDL-C, avoiding blood pressure spikes linked to prior inhibitors.

A pharmaceutical coating uses segmented cationic and anionic polymer layers to control active substance release rates through pH-dependent swelling.

Transitioning to crystalline Form III prevents polymorphic changes while preserving dissolution properties.

1H-pyrazolo[4,3-H]quinazoline compounds inhibit cyclin-dependent kinases with enhanced metabolic stability.

Phenylglyoxaldehyde sorbent binds urea at 1.60 mmol/g, enabling compact dialysis devices without harmful byproducts.

Pre-screening for HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701 prevents hepatotoxicity while maintaining therapeutic efficacy.

A glycosaminoglycan derivative couples a physiologically active substance via a covalent spacer bond to enable controlled drug release.

Fourth-generation heterocyclic inhibitors target triple mutant EGFR variants, overcoming resistance while maintaining favorable toxicity profiles.

A Croton lechleri hydrogel formulation delivers broad-spectrum antimicrobial activity against skin pathogens.

Computer-aided virtual screening identifies small molecule flavonoids that disrupt IL-17A-IL-17RA interaction, replacing costly monoclonal antibodies.

Segmented urea-based photosensitizers target prostate-specific membrane antigen to concentrate within tumors.

2'-Azido nucleoside derivatives inhibit HCV NS5B polymerase, improving therapeutic efficacy while reducing side effects of interferon therapies.

Epigenetic agents target distal enhancer sequences to normalize TGFβ2 expression, addressing insufficient efficacy against fibrosis in current treatments.

Oily nano-domains dispersed in a gelled aqueous phase overcome limited penetration and thermodynamic instability by forming a skin depot.

Structural parameter changes in aminopyrimido naphthyridine compounds overcome drug resistance while maintaining anti-cancer efficacy.

Nitrogen-containing heterocyclic compounds bind to allosteric sites on muscarinic M1 receptors, enhancing receptor function to treat Alzheimer's disease.

Combining soluble and insoluble corticosteroids with sodium hyaluronate provides rapid onset and prolonged action while minimizing unintended diffusion.

Segmented core and tethered particles release immunomodulators before antigens, resolving spatiotemporal control limits in cellular drug delivery systems.

Specific compound formulas modulate S1P1 receptor activity to treat neuropathic pain, overcoming the lack of effective therapeutic options.

Amlexanox analogs with modified ring systems improve therapeutic efficacy by increasing IKK-ε inhibition while overcoming modest potency limitations.

Porous calcium silicate adsorbs oily substances within its specific pore structure, preventing oxidation and lamination defects during compression molding.

Antibody-drug conjugate targets CEACAM6 via cleavable linker, delivering proteolytic payload to degrade BRD2/4 while minimizing systemic toxicity.

Reducing CUL4B protein levels via inhibition sensitizes cancer cells to camptothecin, overcoming treatment resistance.

Modified oligonucleotides with 2'-O-N-alkyl acetamide sugar moieties enhance cellular uptake and pharmacologic activity in muscle tissue.

A polymeric carrier stabilizes amorphous DMT to resolve the contradiction between rapid onset and short duration of action.

A weight reduction method combines a low glucose diet with L-carnitine and Maté to promote fat burning.

A once-daily extended release tacrolimus dosage form maintains therapeutic drug levels through controlled release kinetics.

Free-form amino acid precursors and selenium elevate intracellular glutathione to inhibit Zika virus replication.

Lactitol and lactulose establish osmotic gradients to increase faecal volume while inulin promotes bacterial fermentation for improved consistency.

Substituted imidazopyridazine compounds inhibit Mps-1 kinase to treat proliferative disorders while minimizing chromosomal missegregation.

Heteroaromatic triazole compounds inhibit PDE10A enzyme activity to alleviate cognitive deficits and reduce extrapyramidal side effects in psychiatric patients.

Selective muscarinic M1 and M4 receptor agonists reduce peripheral side effects while improving cognitive function in Alzheimer's disease treatment.

Hot melt extrusion creates a glassy solid dispersion of dibenzo-α-pyrone to overcome low aqueous solubility and bioavailability.

Formula I bicyclic compounds selectively inhibit HDAC6 to improve safety-efficacy profiles over existing treatments.

Sulfonamidoquinoline compounds target the large, flat Cks1-Skp2 interface to inhibit ubiquitination and prevent tumor suppressor degradation.

Phragmitis Rhizoma extract recovers bone marrow suppression caused by anticancer agents through intermediary protection of hematopoietic cells.

Adding molecular weight 145-175 amino acids prevents albumin polymer formation, eliminating anaphylactic risks in taxane therapies.

Phospholipid melatonin nanoparticles solve aqueous instability and low bioavailability, enabling safe neonatal brain injury treatment.

A microemulsion composition enhances racecadotril solubility using surfactants and lipids.

A regulating composition increases Musashi1 expression levels in epidermal and vascular endothelial cells.

Pyrazolo[1,5-a]pyrimidine derivatives overcome poor blood-brain barrier penetration of current ligands by acting as positive allosteric modulators.

Pyrimidine derivatives resolve low potency and specificity issues in inflammatory disorder treatments by targeting histamine H4 receptors.

Crystalline forms B1 and B2 of linagliptin intermediate resolve safety and economy bottlenecks through optimized temperature and solvent parameters.

Inhibiting EGFR reduces neuropathic pain without significant tumor regression.

5,6-substituted pyrimidine derivatives overcome multidrug resistance by altering pharmacological properties to suppress mutant viral strains.

Preliminary pharmacological treatment with mifepristone and octreotide shrinks ACTH-secreting pancreatic neuroendocrine tumors before surgical resection.

Fixed Apadenoson unit doses standardize parenteral administration for myocardial perfusion imaging.

Combining VISTA, TIM-3, and PD-1 pathway inhibitors overcomes single-agent resistance to enhance tumor regression.

Novel benzamide derivatives target serotonin 4 receptors to improve defecation while avoiding cardiovascular risks of existing prokinetics.

Ester-linked retinoid conjugates reduce skin irritation while maintaining photo-aging treatment efficacy.

1,2,4-Oxadiazole derivatives suppress PD-1 signaling with high selectivity, addressing insufficient potency in current immunotherapies.

Oral phosphatidic acid activates mTOR signaling to amplify muscle protein synthesis beyond exercise-induced hypertrophy limits.

Adjusting miR-219 and TLX levels restores neural stem cell self-renewal, addressing defective proliferation in schizophrenia.

Dual targeting of BAFFR and BTK eliminates minimal residual disease, improving response durability in chronic lymphocytic leukemia.

Piperazine carbamates modulate MAGL and ABHD6 enzymes, addressing the lack of effective lipid mediator regulation in current pain treatments.

Segmenting biomarker assessment into allele detection and protein quantification resolves prediction reliability issues caused by inadequate profiles.